Sumitomo Mitsui Trust Holdings Inc. Sells 202,220 Shares of Hologic, Inc. (NASDAQ:HOLX)

Posted by Defense World Staff on Apr 14th, 2023

Hologic logo Sumitomo Mitsui Trust Holdings Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 15.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,080,387 shares of the medical equipment provider’s stock after selling 202,220 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.44% of Hologic worth $80,824,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of HOLX. Macquarie Group Ltd. increased its holdings in shares of Hologic by 227.2% during the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Hologic by 110.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after buying an additional 995,854 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Hologic by 18.7% during the third quarter. Victory Capital Management Inc. now owns 4,266,481 shares of the medical equipment provider’s stock worth $275,273,000 after buying an additional 672,414 shares in the last quarter. Prudential Financial Inc. grew its holdings in Hologic by 246.0% during the first quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock worth $70,730,000 after buying an additional 654,628 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Hologic by 92.8% during the first quarter. Renaissance Technologies LLC now owns 1,300,461 shares of the medical equipment provider’s stock worth $99,901,000 after buying an additional 626,100 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HOLX. Raymond James upped their price target on Hologic from $80.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. Morgan Stanley upped their price target on Hologic from $74.00 to $81.00 and gave the stock an “equal weight” rating in a report on Friday, February 3rd. Cowen upped their price objective on Hologic from $86.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, February 2nd. JPMorgan Chase & Co. upped their price objective on Hologic from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. Finally, Wells Fargo & Company upped their price objective on Hologic from $75.00 to $80.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 10th. Nine equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $84.08.

Hologic Stock Up 1.4 %

Shares of NASDAQ HOLX opened at $84.92 on Friday. Hologic, Inc. has a one year low of $59.78 and a one year high of $86.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.21 and a quick ratio of 3.50. The business’s fifty day moving average price is $80.99 and its 200-day moving average price is $75.91. The stock has a market capitalization of $20.94 billion, a PE ratio of 21.66, a P/E/G ratio of 1.46 and a beta of 1.00.

Hologic (NASDAQ:HOLX – Get Rating) last issued its quarterly earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.17. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a return on equity of 25.12% and a net margin of 22.17%. The business’s revenue for the quarter was down 27.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.17 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post 3.74 EPS for the current year.

Insider Buying and Selling

In related news, insider Benjamin Jordan Cohn sold 9,128 shares of the stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total transaction of $778,435.84. Following the sale, the insider now owns 14,298 shares of the company’s stock, valued at approximately $1,219,333.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.66% of the stock is currently owned by insiders.

About Hologic

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.